Trial Profile
A Phase IV Multicenter Trial to Evaluate Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors PeriPharm
- 10 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 02 May 2016 New trial record
- 27 Apr 2016 Status changed from recruiting to active, no longer recruiting.